ABIOMED INC (ABMD) Stock Fundamental Analysis
USA - NASDAQ:ABMD - US0036541003 - Common Stock
381.02 USD
+0.23 (+0.06%)
381.3 USD
+0.28 (+0.07%)
Taking everything into account, ABMD scores 7 out of 10 in our fundamental rating. ABMD was compared to 190 industry peers in the Health Care Equipment & Supplies industry. ABMD has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. ABMD has a decent growth rate and is not valued too expensively. These ratings would make ABMD suitable for quality investing!
1. Profitability
1.1 Basic Checks
ABMD had positive earnings in the past year.
ABMD had a positive operating cash flow in the past year.
Each year in the past 5 years ABMD has been profitable.
In the past 5 years ABMD always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 15.72%, ABMD belongs to the top of the industry, outperforming 94.52% of the companies in the same industry.
ABMD has a better Return On Equity (17.32%) than 93.61% of its industry peers.
The Return On Invested Capital of ABMD (12.19%) is better than 89.95% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ABMD is significantly above the industry average of 8.88%.
The 3 year average ROIC (29.16%) for ABMD is well above the current ROIC(12.19%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.72% | ||
| ROE | 17.32% | ||
| ROIC | 12.19% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)29.16%
ROIC(5y)N/A
1.3 Margins
ABMD has a Profit Margin of 24.84%. This is amongst the best in the industry. ABMD outperforms 95.43% of its industry peers.
ABMD's Profit Margin has improved in the last couple of years.
ABMD's Operating Margin of 23.66% is amongst the best of the industry. ABMD outperforms 93.61% of its industry peers.
In the last couple of years the Operating Margin of ABMD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.66% | ||
| PM (TTM) | 24.84% | ||
| GM | N/A |
OM growth 3Y-5.22%
OM growth 5Y4.22%
PM growth 3Y-26.75%
PM growth 5Y2.49%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ABMD is creating value.
The number of shares outstanding for ABMD has been increased compared to 1 year ago.
There is no outstanding debt for ABMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ABMD has an Altman-Z score of 68.47. This indicates that ABMD is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ABMD (68.47) is better than 99.54% of its industry peers.
ABMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 68.47 |
ROIC/WACC1.34
WACC9.07%
2.3 Liquidity
ABMD has a Current Ratio of 7.93. This indicates that ABMD is financially healthy and has no problem in meeting its short term obligations.
ABMD's Current ratio of 7.93 is amongst the best of the industry. ABMD outperforms 83.11% of its industry peers.
A Quick Ratio of 7.17 indicates that ABMD has no problem at all paying its short term obligations.
The Quick ratio of ABMD (7.17) is better than 82.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.93 | ||
| Quick Ratio | 7.17 |
3. Growth
3.1 Past
ABMD shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.78%.
ABMD shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 30.92% yearly.
The Revenue has grown by 10.32% in the past year. This is quite good.
ABMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.30% yearly.
EPS 1Y (TTM)-3.78%
EPS 3Y-2.48%
EPS 5Y30.92%
EPS Q2Q%26.21%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y10.27%
Revenue growth 5Y18.3%
Sales Q2Q%7.16%
3.2 Future
Based on estimates for the next years, ABMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.71% on average per year.
ABMD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.13% yearly.
EPS Next Y3.83%
EPS Next 2Y9.68%
EPS Next 3Y14%
EPS Next 5Y15.71%
Revenue Next Year10.29%
Revenue Next 2Y12.97%
Revenue Next 3Y13.62%
Revenue Next 5Y11.13%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 78.72 indicates a quite expensive valuation of ABMD.
Compared to the rest of the industry, the Price/Earnings ratio of ABMD indicates a somewhat cheap valuation: ABMD is cheaper than 71.69% of the companies listed in the same industry.
ABMD is valuated expensively when we compare the Price/Earnings ratio to 27.69, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 66.96, the valuation of ABMD can be described as expensive.
Based on the Price/Forward Earnings ratio, ABMD is valued a bit cheaper than 73.06% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.18. ABMD is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.72 | ||
| Fwd PE | 66.96 |
4.2 Price Multiples
69.41% of the companies in the same industry are more expensive than ABMD, based on the Enterprise Value to EBITDA ratio.
80.82% of the companies in the same industry are more expensive than ABMD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 79.09 | ||
| EV/EBITDA | 55.82 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of ABMD may justify a higher PE ratio.
ABMD's earnings are expected to grow with 14.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)20.54
PEG (5Y)2.55
EPS Next 2Y9.68%
EPS Next 3Y14%
5. Dividend
5.1 Amount
No dividends for ABMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
381.02
+0.23 (+0.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners0%
Inst Owner Change0%
Ins Owners1.66%
Ins Owner Change0%
Market Cap17.18B
Analysts70
Price Target375.36 (-1.49%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.37%
Min EPS beat(2)-5.24%
Max EPS beat(2)15.98%
EPS beat(4)3
Avg EPS beat(4)8.26%
Min EPS beat(4)-5.24%
Max EPS beat(4)15.98%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-14.37%
Min Revenue beat(2)-16.89%
Max Revenue beat(2)-11.85%
Revenue beat(4)0
Avg Revenue beat(4)-11.39%
Min Revenue beat(4)-16.89%
Max Revenue beat(4)-6.39%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.09%
PT rev (3m)N/A
EPS NQ rev (1m)4.13%
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.46%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-3.26%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.36%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.72 | ||
| Fwd PE | 66.96 | ||
| P/S | 16 | ||
| P/FCF | 79.09 | ||
| P/OCF | 68.45 | ||
| P/B | 11.16 | ||
| P/tB | 12.15 | ||
| EV/EBITDA | 55.82 |
EPS(TTM)4.84
EY1.27%
EPS(NY)5.69
Fwd EY1.49%
FCF(TTM)4.82
FCFY1.26%
OCF(TTM)5.57
OCFY1.46%
SpS23.82
BVpS34.15
TBVpS31.36
PEG (NY)20.54
PEG (5Y)2.55
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.72% | ||
| ROE | 17.32% | ||
| ROCE | N/A | ||
| ROIC | 12.19% | ||
| ROICexc | 25.66% | ||
| ROICexgc | 30.76% | ||
| OM | 23.66% | ||
| PM (TTM) | 24.84% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)29.16%
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-10.63%
ROICexcg growth 5Y-2.2%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-5.22%
OM growth 5Y4.22%
PM growth 3Y-26.75%
PM growth 5Y2.49%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 122.5% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 81.43% | ||
| Current Ratio | 7.93 | ||
| Quick Ratio | 7.17 | ||
| Altman-Z | 68.47 |
F-Score6
WACC9.07%
ROIC/WACC1.34
Cap/Depr(3y)188.19%
Cap/Depr(5y)276.96%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)138.14%
Profit Quality(5y)123.31%
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-2.48%
EPS 5Y30.92%
EPS Q2Q%26.21%
EPS Next Y3.83%
EPS Next 2Y9.68%
EPS Next 3Y14%
EPS Next 5Y15.71%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y10.27%
Revenue growth 5Y18.3%
Sales Q2Q%7.16%
Revenue Next Year10.29%
Revenue Next 2Y12.97%
Revenue Next 3Y13.62%
Revenue Next 5Y11.13%
EBIT growth 1Y-2.58%
EBIT growth 3Y4.52%
EBIT growth 5Y23.29%
EBIT Next Year13.8%
EBIT Next 3Y20.3%
EBIT Next 5Y16.96%
FCF growth 1Y-11.7%
FCF growth 3Y6.24%
FCF growth 5Y31%
OCF growth 1Y-11.94%
OCF growth 3Y4.21%
OCF growth 5Y19.91%